Ajeya Samanta

About

I am a dedicated Ph.D. scholar specializing in Pharmaceutical Chemistry, currently pursuing doctoral research at Jadavpur University. With a strong academic foundation in pharmacy and medicinal chemistry, I hold a Master’s degree in Pharmaceutical Sciences and have consistently demonstrated a passion for drug discovery and development. My research focuses on the synthesis and characterization of novel therapeutic compounds targeting mainly breast and cervical cancer, aiming to enhance efficacy and reduce side effects through innovative molecular design.

Under the guidance of esteemed faculty, Prof. Tapan Kumar Maity I have contributed to several interdisciplinary projects, collaborating with experts in pharmacology, biochemistry, and computational modelling.

Driven by curiosity, precision, and a deep commitment to improving global health, I will continue to pursue excellence in the ever-evolving field of pharmaceutical chemistry.

Employment

• JIS University Assistant Professor
  2026 - 2026
• Eminent College of Pharmaceutical Technology Assistant Professor
  2019 - 2022

Education

• Jadavpur University Ph.D.
  2022 - Present
• Jadavpur University M.Pharm
  2017 - 2019
• BCDA College of Pharmacy & Technology B.Pharm
  2013 - 2017

Projects & Funding

Projects & funding information is unavailable.

Publications (13)

• 1,3,4-oxadiazole-tethered alkylidene acetohydrazides as potential anticancer agents: synthesis and in vitro biological evaluation
  Journal of Molecular Structure 2026 DOI: 10.1016/j.molstruc.2026.147113
  +Save
• Synthesis, XRD-sc study and antiproliferative, apoptotic & anti-angiogenic potency of 1,3,4-thiadiazole and 1,3-thiazolidine-4-one scaffold-based hybrid compounds (Part-II): in vitro cell-based anticancer studies
  Journal of Molecular Structure 2026 DOI: 10.1016/j.molstruc.2025.143999
  +Save
• Exploring the therapeutic potentials of cuminaldehyde: a comprehensive review of biological activities, mechanisms, and novel delivery systems
  Phytochemistry Reviews 2025 DOI: 10.1007/s11101-025-10069-x
  +Save
• Synthesis, crystal structure, and in vitro evaluation of newer 2,4-thiazolidinedione hybrids as α-glucosidase inhibitors
  Future Medicinal Chemistry 2025 DOI: 10.1080/17568919.2025.2550933
  +Save
• 1,3,4-Oxadiazole-based EGFR inhibitors as anticancer therapeutics: SAR study and binding mode of interaction analysis
  European Journal of Medicinal Chemistry Reports 2025 DOI: 10.1016/j.ejmcr.2025.100265
  +Save
• Unveiling the Anti-cancer Potential of Oxadiazole Derivatives: A Comprehensive Exploration of Structure-Activity Relationships and Chemico-Biological Insights
  Medicinal Chemistry 2025 DOI: 10.2174/0115734064329573240823113924
  +Save
• Synthesis, single crystal XRD, in vitro evaluation, molecular docking and ADMET studies of cuminaldehyde-thiazolidine-2,4-dione hybrids as potential α-glucosidase inhibitors
  Journal of Molecular Structure 2025 DOI: 10.1016/j.molstruc.2025.141510
  +Save
• Significance of TRAIL/Apo-2 ligand and its death receptors in apoptosis and necroptosis signalling: Implications for cancer-targeted therapeutics
  Biochemical Pharmacology 2024 DOI: 10.1016/j.bcp.2024.116041
  +Save
• Synthesis and antiproliferative potency of 1,3,4-thiadiazole and 1,3-thiazolidine-4-one based new binary heterocyclic molecules: in vitro cell-based anticancer studies
  RSC Medicinal Chemistry 2024 DOI: 10.1039/d4md00279b
  +Save
• Synthetic GPR40/FFAR1 agonists: An exhaustive survey on the most recent chemical classes and their structure-activity relationships
  European Journal of Medicinal Chemistry 2024 DOI: 10.1016/j.ejmech.2023.115990
  +Save